相关实验视频

Updated: Jun 24, 2025

How to Study Basement Membrane Stiffness as a Biophysical Trigger in Prostate Cancer and Other Age-related Pathologies or Metabolic Diseases

How to Study Basement Membrane Stiffness as a Biophysical Trigger in Prostate Cancer and Other Age-related Pathologies or Metabolic Diseases

Published on: September 20, 2016

卡维迪醇对人类前列腺组织收缩性和树皮细胞生长的影响,这表明其潜在的临床影响

Sheng Hu¹, A Elif Müderrisoglu¹, Anna Ciotkowska¹

¹Department of Urology, LMU University Hospital, LMU Munich, Munich, Germany.

Pharmacological reports : PR

|June 10, 2024

概括

卡维迪醇对抗人类前列腺中的α1-腺素受体,影响光滑肌肉收缩和肌细胞生长. 它对前列腺组织和细胞功能的影响是剂量依赖的,可能与偏向性激动有关.

科学领域:

药理学药理学是指药理学的学科.
泌尿器科泌尿器科泌尿器科泌尿器科
细胞生物学细胞生物学

背景情况:

作为一种抗高血压药物,卡维迪醇也对抗血管α1-上腺体受体.
阿尔法1-上腺受体对于管理良性前列腺增生 (BPH) 消除症状至关重要.
卡维迪醇对人类前列腺的作用在很大程度上仍未被描述.

研究的目的:

为了研究卡维迪洛对人类前列腺组织收缩的影响.
为了检查卡维迪洛对人类前列腺侧膜细胞生长和活力的影响.
为了确定卡维迪洛在临床上可达到的度下是否具有前列腺作用.

主要方法:

来自激进前列腺切除术的人类前列腺组织被用于评估收缩反应.
电场刺激 (EFS) 和α1-激动剂 (乙烯酸,甲胺,诺拉德林) 诱导的收缩.
培养的人类前列腺 stromal 细胞被用于评估生长,活力和增殖.

主要成果:

卡维迪洛尔将激动剂的度-反应曲线向右移动,表明α1-上腺受体对抗性.
以剂量依赖的方式,EFS诱导的收缩被卡维迪醇显著减少.
卡维迪醇对树皮细胞的增殖和殖民地形成表现出双向作用,并且在较高度下降了殖民地大小和活力.

结论:

卡维迪醇在接近治疗性血水平的度下对抗人类前列腺中的α1-上腺受体.
在体外,卡维迪洛对前列腺收缩的作用类似于用于BPH的α1抑制剂,尽管需要更高度.
结构细胞生长的复杂,动态效应表明卡维迪洛的潜在"偏差激进主义".

关键词:

这是一种α1阻断剂.良性前列腺增生症 (BPH) 是一种卡尔维迪醇是一种下尿路症状 (LUTS) 是指下尿路的症状.前列腺光滑肌的收缩收缩虚无的症状虚无的症状

更多相关视频

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy

Published on: December 28, 2021

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing

Published on: August 14, 2019

相关概念视频

Heart Failure Drugs: β-Blockers

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...

Antihypertensive Drugs: Vasodilators

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...